Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial.

Lancet regional health. Americas·2026
Same author

Superficial intercostal plane blocks for post-sternotomy pain control rationale and design for the EPOCH CardioLink-10 randomized clinical trial.

Current opinion in cardiology·2026
Same author

Successful Pregnancy and Childbirth Decades After Renal Transplant.

Journal of obstetrics and gynaecology of India·2026
Same author

Transcatheter Retrieval of Mitral Bioprosthetic Valve Vegetation With Extended Embolic Protection: A Case Report.

Journal of the Society for Cardiovascular Angiography & Interventions·2026
Same author

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis.

British journal of haematology·2026
Same author

Neoadjuvant Therapy for Localized Pancreatic Cancer.

Cancers·2026
Same journal

Letter to the Editor on "Clinical profile and optical coherence tomography based morphological characteristics of coronary in-stent restenosis: A cross-sectional study".

Indian heart journal·2026
Same journal

Evolving spectrum and outcomes of infective endocarditis in North India: A comparative analysis between people who inject drugs and those who do not.

Indian heart journal·2026
Same journal

Medical management of hypertrophic cardiomyopathy.

Indian heart journal·2026
Same journal

Response to the Letter to the Editor, "Reappraising the role of CMRI in HFpEF: A tiny step in the black and white world of HFpEF".

Indian heart journal·2026
Same journal

Indian society of electrocardiology position statement on improving CPR awareness in the Indian public.

Indian heart journal·2026
Same journal

Intracoronary thrombus in ST-segment elevation myocardial infarction: Practical management strategies for the interventional cardiologist.

Indian heart journal·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Beta blockers & left ventricular hypertrophy regression.

Thomas George1, Mullasari S Ajit, Georgi Abraham

  • 1Institute of Cardiovascular Diseases, The Madras Medical Mission, Chennai, Tamil Nadu, India.

Indian Heart Journal
|December 25, 2010
PubMed
Summary
This summary is machine-generated.

Left ventricular hypertrophy (LVH) is a key predictor of cardiovascular events in hypertensive patients. This review examines the role of beta blockers in potentially regressing LVH, despite limitations in current research.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of adverse cardiovascular events, especially in hypertensive individuals.
  • LVH prevalence correlates with age and hypertension severity, impacting prognostication and therapeutic choices.

Purpose of the Study:

  • To review current evidence on the efficacy of beta blockers in regressing left ventricular hypertrophy.
  • To highlight inconsistencies in LVH definition and regression documentation within existing meta-analyses.

Main Methods:

  • Review of existing literature and meta-analyses concerning LVH regression.
  • Analysis of antihypertensive drug classes, focusing on beta blockers' role.

Main Results:

  • Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are more potent in regressing LVH compared to other antihypertensives.
  • Beta blockers, particularly newer cardio-selective agents, may have a role in LVH regression, though potentially minor.

Conclusions:

  • Consistent criteria for defining and documenting LVH regression are lacking in current meta-analyses.
  • Further research is needed to clarify the precise role and efficacy of beta blockers in LVH regression.